Trials that use: P-values
New to this method? Read the tutorial →
20,601 results
- Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23): Complete Statistical AnalysisIndependent statistical analysis of Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02378480).
- Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13): Complete Statistical AnalysisIndependent statistical analysis of Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02531438).
- Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia: Complete Statistical AnalysisIndependent statistical analysis of Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04779242).
- Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma: Complete Statistical AnalysisIndependent statistical analysis of Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy: Complete Statistical AnalysisIndependent statistical analysis of Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy: primary endpoint results, effect estimate with confidence interval, sample-size…
- Omalizumab in the Treatment of Peanut Allergy: Complete Statistical AnalysisIndependent statistical analysis of Omalizumab in the Treatment of Peanut Allergy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00949078).
- Omarigliptin (MK-3102) Clinical Trial – Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015): Complete Statistical AnalysisIndependent statistical analysis of Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015): primary endpoint results, effect estimate with confidence interval,…
- Omega Tots Long Term Follow-up: Complete Statistical AnalysisIndependent statistical analysis of Omega Tots Long Term Follow-up: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05191823).
- Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits: Complete Statistical AnalysisIndependent statistical analysis of Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder: Complete Statistical AnalysisIndependent statistical analysis of Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00511810).
- Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder: Complete Statistical AnalysisIndependent statistical analysis of Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01694667).
- Omega-3 Fatty Acids For Treatment Of Young Children With Autism (OMG): Complete Statistical AnalysisIndependent statistical analysis of Omega-3 Fatty Acids For Treatment Of Young Children With Autism (OMG): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- OmegaREMODELIndependent statistical analysis of Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Omentectomy and Metabolic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Omentectomy and Metabolic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00923260).
- Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT: Complete Statistical AnalysisIndependent statistical analysis of Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- OMS302-ILR-003Independent statistical analysis of Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- OMWaNAIndependent statistical analysis of Kangaroo Mother Care Before Stabilisation Amongst Low Birth Weight Neonates in Africa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- ON TARGET DMIndependent statistical analysis of Comparison of Type 2 Diabetes Pharmacotherapy Regimens: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05073692).
- ON TRAXIndependent statistical analysis of Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- On-Eye Evaluation of Contact Lens Axis Location: Complete Statistical AnalysisIndependent statistical analysis of On-Eye Evaluation of Contact Lens Axis Location: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02100410).
- On-OffIndependent statistical analysis of On Versus Off Pump Myocardial Revascularization Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01290952).
- ON-Q Pump Infusion of Ketorolac and Ropivacaine at the Wound Site for Postoperative Pain Management: Complete Statistical AnalysisIndependent statistical analysis of ON-Q Pump Infusion of Ketorolac and Ropivacaine at the Wound Site for Postoperative Pain Management: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- ONBOARDIndependent statistical analysis of Overcoming Barriers and Obstacles to Adopting Diabetes Devices (ONBOARD) Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04672655).
- ONC201 in Adults With Recurrent H3 K27M-mutant Glioma: Complete Statistical AnalysisIndependent statistical analysis of ONC201 in Adults With Recurrent H3 K27M-mutant Glioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03295396).
- ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03394027).
- Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00837200).
- Once Versus Twice Daily Iron Supplementation in Pregnant Women: Complete Statistical AnalysisIndependent statistical analysis of Once Versus Twice Daily Iron Supplementation in Pregnant Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02839096).
- Once-Daily Asenapine for Schizophrenia: Complete Statistical AnalysisIndependent statistical analysis of Once-Daily Asenapine for Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01549041).
- Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures: Complete Statistical AnalysisIndependent statistical analysis of Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures: primary endpoint results, effect estimate with confidence interval,…
- Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients: Complete Statistical AnalysisIndependent statistical analysis of Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- onceMRKIndependent statistical analysis of Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292): primary…
- Oncolo-GISTIndependent statistical analysis of Giving Information Systematically and Transparently in Lung and GI Cancer Phase 2: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Ondansetron and the QT Interval In Adult Emergency Department Patients: Complete Statistical AnalysisIndependent statistical analysis of Ondansetron and the QT Interval In Adult Emergency Department Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01759420).
- Ondansetron as a Strategy for Reducing Propofol Injection Pain in Pediatrics: a Randomized Controlled Trial: Complete Statistical AnalysisIndependent statistical analysis of Ondansetron as a Strategy for Reducing Propofol Injection Pain in Pediatrics: a Randomized Controlled Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions: Complete Statistical AnalysisIndependent statistical analysis of Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00934180).
- Ondansetron Plus Dexamethasone With or Without Metoclopramide as Antiemetic Prophylaxis After Receiving Cisplatin: Complete Statistical AnalysisIndependent statistical analysis of Ondansetron Plus Dexamethasone With or Without Metoclopramide as Antiemetic Prophylaxis After Receiving Cisplatin: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- One Touch VerioIQ US Clinical Outcomes Study: Complete Statistical AnalysisIndependent statistical analysis of One Touch VerioIQ US Clinical Outcomes Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01627899).
- One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study: Complete Statistical AnalysisIndependent statistical analysis of One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00580788).
- One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age: Complete Statistical AnalysisIndependent statistical analysis of One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response…
- One Year Study of Rifaximin Delayed Release (DR) in Crohn’s Disease: Complete Statistical AnalysisIndependent statistical analysis of One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- One-Day Acceptance and Commitment Training Intervention in Primary Care Patients: Complete Statistical AnalysisIndependent statistical analysis of One-Day Acceptance and Commitment Training Intervention in Primary Care Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01879800).
- One-Day Dispensing Clinical Evaluation of SofLens Daily Disposable Lenses Compared to a Marketed 1 Day Contact Lens: Complete Statistical AnalysisIndependent statistical analysis of One-Day Dispensing Clinical Evaluation of SofLens Daily Disposable Lenses Compared to a Marketed 1 Day Contact Lens: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- One-Day Life Skills Workshop for Veterans With TBI, Pain and Psychopathology: Complete Statistical AnalysisIndependent statistical analysis of One-Day Life Skills Workshop for Veterans With TBI, Pain and Psychopathology: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Online Caregiver Psychoeducation and Support for Alzheimer’s: Complete Statistical AnalysisIndependent statistical analysis of Online Caregiver Psychoeducation and Support for Alzheimer's: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00416078).
- Online MBCT Program for University Students: Complete Statistical AnalysisIndependent statistical analysis of Online MBCT Program for University Students: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05804877).
- Online Social Networking for HIV Prevention: Complete Statistical AnalysisIndependent statistical analysis of Online Social Networking for HIV Prevention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00725959).
- Online Survey in Studying Smoking Attitudes and Behaviors Among Current Smokers: Complete Statistical AnalysisIndependent statistical analysis of Online Survey in Studying Smoking Attitudes and Behaviors Among Current Smokers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Online Trial Examining Validity and Reliability of the Shared Decision Making Process Survey: Complete Statistical AnalysisIndependent statistical analysis of Online Trial Examining Validity and Reliability of the Shared Decision Making Process Survey: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…